Clopidogrel

Generic Name: Clopidogrel

Brand Names: Duoplavin, Plavix, Zyllt, Clopidogrel BGR (previously Zylagren), Clopidogrel TAD, Clopidogrel ratiopharm, Clopidogrel Zentiva (previously Clopidogrel Winthrop), Clopidogrel Krka, Clopidogrel Krka d.d. (previously Zopya), Clopidogrel Teva (hydrogen sulphate), Clopidogrel HCS, Iscover, Grepid, Clopidogrel Taw Pharma (previously Clopidogrel Mylan), Clopidogrel Viatris (previously Clopidogrel Taw Pharma)

Drug Type: Small Molecule

Chemical Formula: C_₁₆H_₁₆ClNO_₂S

CAS Number: 113665-84-2

Unique Ingredient Identifier: A74586SNO7

Background: Clopidogrel is a prodrug of a platelet inhibitor used to reduce the risk of myocardial infarction and stroke. Clopidogrel is indicated to reduce the risk of myocardial infarction for patients with non-ST elevated acute coronary syndrome (ACS), patients with ST-elevated myocardial infarction, and in recent MI, stroke, or established peripheral arterial disease,

It has been shown to be superior to aspirin in reducing cardiovascular outcomes in patients with cardiovascular disease and provides additional benefit to patients with acute coronary syndromes already taking aspirin.

Clopidogrel was granted FDA approval on 17 November 1997.

Indication: 1.用于新近心肌梗死、新近脑卒中或确诊的周围动脉病变患者，可减少新的缺血性脑卒中、心肌梗死和死亡等心脑血管事件的符合终点；

2.用于急性冠状动脉综合征（不稳定心绞痛和非ST段抬高心肌梗死）患者；

3.用于冠状动脉支架置入术后预防支架内血栓形成（与阿司匹林联用）。

Associated Conditions: Acute Coronary Syndrome (ACS), Acute Myocardial Infarction (AMI), Cardiovascular Events, Atherothrombotic events

Associated Therapies: -

Clinical Trials

Harmonizing Optimal Strategy for Treatment of Coronary Artery Stenosis- EXtended Antiplatelet Monotherapy (HOST-EXAM)

Phase 4

Completed

Conditions: Coronary Heart Disease

Interventions: Drug: Clopidogrel
Drug: Aspirin

First Posted Date: 2014-01-23

Last Posted Date: 2021-04-14

Lead Sponsor: Seoul National University Hospital

Target Recruit Count: 5530

Registration Number: NCT02044250

Locations: 🇰🇷
Seoul National University Hospital, Seoul, Korea, Republic of

Impact of Ticagrelor on the Endothelial Healing Following Drug-eluting Stent Implantation in the Patients With Acute Coronary Syndrome

Phase 4

Terminated

Conditions: Unstable Angina (Intermediate Coronary Syndrome)
Acute Coronary Syndrome
Acute Myocardial Infarction

Interventions: Drug: Ticagrelor
Drug: Clopidogrel

First Posted Date: 2014-01-15

Last Posted Date: 2019-03-29

Lead Sponsor: Yonsei University

Target Recruit Count: 148

Registration Number: NCT02037412

Locations: 🇰🇷
Division of Cardiology, Yonsei Cardiovascular Hospital, Yonsei University College of Medicine, Seoul, Korea, Republic of

Safety Study of APD-791 With Aspirin and/or Clopidogrel

Phase 1

Terminated

Conditions: Acute Coronary Syndrome

Interventions: Drug: Clopidogrel
Drug: Aspirin
Drug: Placebo
Drug: APD791

First Posted Date: 2014-01-13

Last Posted Date: 2019-02-15

Lead Sponsor: IlDong Pharmaceutical Co Ltd

Target Recruit Count: 16

Registration Number: NCT02034292

Comparison of Clopidogrel and Ticagrelor on Microvascular Dysfunction in ST-Segment Elevation Myocardial Infarction

Phase 4

Completed

Conditions: Non-ST Segment Elevation Myocardial Infarction
ST Segment Elevation Myocardial Infarction

Interventions: Drug: Clopidogrel
Drug: Ticagrelor

First Posted Date: 2014-01-01

Last Posted Date: 2015-10-01

Lead Sponsor: Inha University Hospital

Target Recruit Count: 76

Registration Number: NCT02026219

Locations: 🇰🇷
Inha University Hospital, Incheon, Korea, Republic of

Cilostazol Stroke Prevention Study for Antiplatelet Combination

Phase 4

Completed

Conditions: Noncardioembolic Cerebral Infarction

Interventions: Drug: aspirin
Drug: clopidogrel
Drug: cilostazol

First Posted Date: 2013-11-26

Last Posted Date: 2019-03-28

Lead Sponsor: Japan Cardiovascular Research Foundation

Target Recruit Count: 1884

Registration Number: NCT01995370

Locations: 🇯🇵
Japan Cardiovascular Research Foundation, Osaka, Japan

Genotype Guided Versus Conventional Approach in Selection of Oral P2Y12 Receptor Blocker in Chinese Patients Suffering From Acute Coronary Syndrome

Phase 4

Completed

Conditions: Acute Coronary Syndrome

Interventions: Drug: Clopidogrel
Drug: Ticagrelor

First Posted Date: 2013-11-26

Last Posted Date: 2015-12-02

Lead Sponsor: The University of Hong Kong

Target Recruit Count: 133

Registration Number: NCT01994941

Locations: 🇭🇰
Department of Medicine, the University of Hong Kong, Queen Mary Hospital, Hospital Authority, Hong Kong, Hong Kong

Cangrelor to Clopidogrel or Prasugrel Transition Study

Phase 2

Completed

Conditions: Coronary Artery Disease (CAD)

Interventions: Drug: Cangrelor
Drug: Prasugrel
Drug: Clopidogrel

First Posted Date: 2013-11-08

Last Posted Date: 2020-02-26

Lead Sponsor: The Medicines Company

Target Recruit Count: 15

Registration Number: NCT01979445

Locations: 🇺🇸
Fletcher Allen Health Care, Burlington, Vermont, United States

Testing Responsiveness to Platelet Inhibition on Chronic Antiplatelet Treatment For Acute Coronary Syndromes Trial

Phase 4

Completed

Conditions: Acute Coronary Syndrome

Interventions: Drug: Prasugrel
Drug: Clopidogrel

First Posted Date: 2013-10-10

Last Posted Date: 2019-03-01

Lead Sponsor: LMU Klinikum

Target Recruit Count: 2600

Registration Number: NCT01959451

Locations: 🇦🇹
Wilhelminenspital Wien, 3. Medizinische Abteilung, Vienna, Austria
🇦🇹
Medizin-Universität Graz, Univ. Klinik für Innere Medizin, Graz, Austria
🇭🇺
Heart Center Szeged, Szeged, Hungary

and more 30 locations